Study on Serum Cystatin C and PET-DAT in Patients With Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

The Relationship Between Serum Cystatin C and PET-DAT Study in Patients With Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04926909
• Other study ID #: 2020-079
• Status: Recruiting
• Start date: July 1, 2020
• Est. completion date: August 1, 2021

Study information

• Verified date: March 2021
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: BaoRong Zhang, MD
• Phone: 13958167260
• Email: brzhang[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To investigate the relationship between serum cystatin C and dopamine receptor(DAT) loss in patients with parkinson's disease(PD)

Description:

Number of people suffered from Parkinson disease (PD) is increasing every year. PET imaging of dopamine transport receptors（DAT） serves as the gold standard for the diagnosis and monitoring of PD development. However, due to high costs and radiation reasons, it is not suitable for long-term follow-up. Serum cystatin C can be easily obtained and cheap as an indicator. In recent years, studies have gradually found that it is related to the progression of H&Y staging of Parkinson's disease. To this extent, we want to further explore whether it can reflect the loss of DAT in the brain. Explore whether it can partially replace the role of DAT imaging for future clinical evaluation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 121
• Est. completion date: August 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients aged between 20 and 80 years and whose laboratory results included the levels of serum Cystatin C within a month from the PET-DAT were recruited.

Exclusion Criteria:

• To make the study cohort more homogeneous, PD patients with either a long-standing duration (=5 years) or advanced Hoehn and Yahr (H&Y) staging (=3) were excluded.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
China	Second Affiliated Hospital, College of Medicine, Zhejiang University	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cystatin C assesses the loss of dopaminergic neurons	Explore whether Cystatin C can respond to the loss of dopaminergic neurons	through study completion, an average of 1 year